TrialJournal of affective disorders2025

Metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder.

Sudeepa Bhattacharyya et al.PubMed ↗Publisher ↗

No numbers read from the abstract.